Autoclaves for economical operation

In business since 1988, the autoclave specialists at Valencia, CA, US-based ASC Process Systems had three of its smaller products on the CAMX show floor but also highlighted the ASC-built autoclave — the world’s largest, with a working are of 9.14m by 22.86m — that now cures fuselage sections in Charleston, SC, US, for the Boeing Co.’s (Chicago, IL, US) 787 Dreamliner.

Related Topics:

Related Suppliers

In business since 1988, the autoclave specialists at Valencia, CA, US-based ASC Process Systems had three of its smaller products on the CAMX show floor but also highlighted the ASC-built autoclave — the world’s largest, with a working are of 9.14m by 22.86m — that now cures fuselage sections in Charleston, SC, US, for the Boeing Co.’s (Chicago, IL, US) 787 Dreamliner.

But the company also drew booth visitor attention on its trademarked Econoclave, touted as the world’s most popular composite curing autoclave. As aerocomposites manufacturers seek ways to cut cost and increase production rates, the autoclave, that indispensable tool for ensuring proper consolidation and specified low void content in flight-critical aircraft components, has come under scrutiny because of the high capital investment and high cost of operation. ASC’s Econoclave was designed to reduce both. The system’s popularity is attributed to its comparatively low operating cost, the result, in part, of ASC’s proprietary CPC (Composite Processing Control) software and control system. ASC claims that this aerospace-grade autoclave can save the user tens of thousands of dollars per year in electricity, compressed air and nitrogen consumption, compared to conventional autoclave systems.  Standard models are available in sizes that range from 0.3m to 4.6m in diameter and 0.61m to 6.1m in length.

Claiming more than 1,500 satisfied customers, worldwide, ASC supports and services its systems from its Valencia headquarters and branch locations in Poole, UK and Bejing, China. 

Editor Pick

Royal DSM acquires remaining part of DSM-AGI joint venture

Royal DSM (Heerlen, Netherlands) announced  on August 9 that it has concluded the acquisition of the outstanding 49% of shares in its DSM-AGI joint venture.